[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RU2001131722A - 5- [4- (6-Methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy) benzyl] thiazolidin-2,4-di hydrochloride having hypoglycemic activity - Google Patents

5- [4- (6-Methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy) benzyl] thiazolidin-2,4-di hydrochloride having hypoglycemic activity

Info

Publication number
RU2001131722A
RU2001131722A RU2001131722/04A RU2001131722A RU2001131722A RU 2001131722 A RU2001131722 A RU 2001131722A RU 2001131722/04 A RU2001131722/04 A RU 2001131722/04A RU 2001131722 A RU2001131722 A RU 2001131722A RU 2001131722 A RU2001131722 A RU 2001131722A
Authority
RU
Russia
Prior art keywords
compound according
active ingredient
agent
mammal
medicament
Prior art date
Application number
RU2001131722/04A
Other languages
Russian (ru)
Other versions
RU2214410C2 (en
Inventor
Такаси ФУДЗИТА
Тосихико Фудзивара
Такаси ИЗУМИ
Original Assignee
Санкио Компани, Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санкио Компани, Лимитед filed Critical Санкио Компани, Лимитед
Publication of RU2001131722A publication Critical patent/RU2001131722A/en
Application granted granted Critical
Publication of RU2214410C2 publication Critical patent/RU2214410C2/en

Links

Claims (14)

1. 5-[4-(6-Метокси-1-метил-1Н-бензимидазол-2-илметокси)бензил]тиазолидин-2,4-дион гидрохлорид.1.5- [4- (6-Methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy) benzyl] thiazolidin-2,4-dione hydrochloride. 2. Лекарственное средство, содержащее соединение по п.1 в качестве активного ингредиента.2. A medicament containing a compound according to claim 1 as an active ingredient. 3. Профилактическое или терапевтическое средство для гипергликемии, содержащее соединение по п.1 в качестве активного ингредиента.3. A prophylactic or therapeutic agent for hyperglycemia, containing the compound according to claim 1 as an active ingredient. 4. Профилактическое или терапевтическое средство против снижения толерантности к глюкозе, содержащее соединение по п.1 в качестве активного ингредиента.4. A prophylactic or therapeutic agent for reducing glucose tolerance containing the compound according to claim 1 as an active ingredient. 5. Профилактическое или терапевтическое средство против осложнений диабета, содержащее соединение по п.1 в качестве активного ингредиента.5. A prophylactic or therapeutic agent for diabetes complications, comprising the compound of claim 1 as an active ingredient. 6. Профилактическое или терапевтическое средство против заболеваний, вызванных инсулиновой толерантностью, содержащее соединение по п.1 в качестве активного ингредиента.6. A prophylactic or therapeutic agent against diseases caused by insulin tolerance, containing the compound according to claim 1 as an active ingredient. 7. Применение соединения по п.1 в качестве активного ингредиента лекарственного средства для улучшения состояния при инсулиновой резистентности.7. The use of a compound according to claim 1 as an active ingredient of a medicament for improving the condition of insulin resistance. 8. Применение соединения по п.1 в качестве активного ингредиента лекарственного средства для профилактики или лечения гипергликемии.8. The use of a compound according to claim 1 as an active ingredient in a medicament for the prevention or treatment of hyperglycemia. 9. Применение соединения по п.1 в качестве активного ингредиента лекарственного средства для профилактики или лечения осложнений диабета.9. The use of a compound according to claim 1 as an active ingredient in a medicament for the prevention or treatment of diabetes complications. 10. Применение соединения по п.1 в качестве активного ингредиента лекарственного средства для профилактики или лечения сниженной толерантности к глюкозе.10. The use of a compound according to claim 1 as an active ingredient in a medicament for the prevention or treatment of reduced glucose tolerance. 11. Способ улучшения состояния при инсулиновой резистентности у млекопитающего, включающий введение указанному млекопитающему эффективного количества средства, улучшающего состояние при инсулиновой резистентности, причем указанное улучшающее состояние при инсулиновой резистентности средство является соединением по п.1.11. A method of improving insulin resistance in a mammal, comprising administering to said mammal an effective amount of an insulin resistance improving agent, said insulin resistance improving agent is a compound according to claim 1. 12. Способ профилактики или лечения гипергликемии у млекопитающего, включающий введение указанному млекопитающему эффективного количества антигипергликемического средства, причем указанным антигипергликемическим средством является соединение по п.1.12. A method for preventing or treating hyperglycemia in a mammal, comprising administering to said mammal an effective amount of an antihyperglycemic agent, said antihyperglycemic agent being a compound according to claim 1. 13. Способ профилактики или лечения осложнений диабета у млекопитающего, включающий введение указанному млекопитающему эффективного количества средства, эффективного для профилактики или лечения осложнений диабета, причем указанным средством является соединение по п.1.13. A method for preventing or treating diabetes complications in a mammal, comprising administering to said mammal an effective amount of an agent effective for preventing or treating diabetes complications, said agent being a compound according to claim 1. 14. Способ профилактики или лечения сниженной толерантности к глюкозе у млекопитающего, включающий введение указанному млекопитающему эффективного количества средства, эффективного для профилактики или лечения сниженной толерантности к глюкозе, причем указанным средством является соединение по п.1.14. A method for preventing or treating a reduced glucose tolerance in a mammal, comprising administering to said mammal an effective amount of an agent effective for preventing or treating a reduced glucose tolerance, said agent being a compound according to claim 1.
RU2001131722/04A 1999-05-24 2000-05-24 Methoxy)benzyl]-thiazolidine-2,4-dione hydrochloride eliciting hypoglycemic activity RU2214410C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11/143513 1999-05-24
JP14351399 1999-05-24

Publications (2)

Publication Number Publication Date
RU2001131722A true RU2001131722A (en) 2003-06-20
RU2214410C2 RU2214410C2 (en) 2003-10-20

Family

ID=15340495

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001131722/04A RU2214410C2 (en) 1999-05-24 2000-05-24 Methoxy)benzyl]-thiazolidine-2,4-dione hydrochloride eliciting hypoglycemic activity

Country Status (25)

Country Link
US (1) US6706746B2 (en)
EP (1) EP1180519B1 (en)
KR (2) KR100748053B1 (en)
CN (1) CN1156473C (en)
AT (1) ATE294799T1 (en)
AU (1) AU763731B2 (en)
BR (1) BR0010914A (en)
CA (1) CA2375017C (en)
CZ (1) CZ297927B6 (en)
DE (1) DE60019919T2 (en)
DK (1) DK1180519T3 (en)
ES (1) ES2240099T3 (en)
HK (1) HK1042087B (en)
HU (1) HU229340B1 (en)
IL (1) IL146568A0 (en)
MX (1) MXPA01012044A (en)
NO (1) NO321578B1 (en)
NZ (1) NZ515570A (en)
PL (1) PL209389B1 (en)
PT (1) PT1180519E (en)
RU (1) RU2214410C2 (en)
TR (1) TR200103353T2 (en)
TW (1) TWI284533B (en)
WO (1) WO2000071540A1 (en)
ZA (1) ZA200109576B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284533B (en) * 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
EP1695716A2 (en) 2000-12-26 2006-08-30 Sankyo Company, Limited Medicinal compositions containing diuretics and insulin sensitizers
US6756399B2 (en) * 2001-06-29 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
AU2003220855A1 (en) * 2002-04-01 2003-10-13 Sankyo Company, Limited Medicinal antitumor composition
WO2004013109A1 (en) * 2002-08-02 2004-02-12 Sankyo Company, Limited Resorcinol derivative
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
JPWO2004106542A1 (en) 2003-05-29 2006-07-20 三共株式会社 Insulin resistance improving agent and screening method thereof
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
ATE490771T1 (en) * 2003-10-24 2010-12-15 Santen Pharmaceutical Co Ltd THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISEASES
EP1566202A1 (en) * 2004-02-23 2005-08-24 Sahltech I Göteborg AB Use of resistin antagonists in the treatment of rheumatoid arthritis
CN1972715A (en) * 2004-03-29 2007-05-30 三共株式会社 Therapeutic agent for diabetes mellitus containing insulin resistance improving agent
TW200608967A (en) 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
CA2590883A1 (en) * 2004-12-13 2006-06-22 Daiichi Sankyo Company, Limited Medicinal composition for treating diabetes
CA2591416A1 (en) * 2004-12-15 2006-06-22 Daiichi Sankyo Company Limited Medicinal composition containing fbpase inhibitor
TW200637856A (en) * 2005-01-24 2006-11-01 Sankyo Co Process for producing thiazolidinedion compound and intermediate thereof
JPWO2006126673A1 (en) * 2005-05-27 2008-12-25 第一三共株式会社 Antidiabetic drugs in combination
WO2007007656A1 (en) * 2005-07-08 2007-01-18 Daiichi Sankyo Company, Limited Pharmaceutical composition containing thiazolidinedione compound
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
JP5186217B2 (en) 2005-11-28 2013-04-17 千寿製薬株式会社 PPAR agonist-containing medicine
RU2456276C2 (en) * 2007-04-05 2012-07-20 Дайити Санкио Компани, Лимитед Benzimidazole derivatives, based pharmaceutical composition and methods of using them
CA2687957C (en) 2007-05-21 2014-11-25 Senju Pharmaceutical Co., Ltd. Pharmaceutical containing ppar.delta. agonist
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
BRPI1006113A2 (en) 2009-03-05 2016-02-16 Daiichi Sankyo Co Ltd "pyridine derivative".
AU2014236510A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
WO2015109037A1 (en) 2014-01-15 2015-07-23 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118474A (en) * 1995-06-01 2001-08-08 Sankyo Co Benzimidazole derivatives and pharmaceutical compositions containing the same
CA2180296C (en) 1995-07-03 2007-01-09 Yoshio Tsujita Treatment of arteriosclerosis and xanthoma
TWI284533B (en) * 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
PL352681A1 (en) * 1999-07-19 2003-09-08 Sankyo Company, Limited Preventive and therapeutic agents for cancer

Similar Documents

Publication Publication Date Title
RU2001131722A (en) 5- [4- (6-Methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy) benzyl] thiazolidin-2,4-di hydrochloride having hypoglycemic activity
EP1377278B1 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
MY129897A (en) Use of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione and metformin for the treatment of diabetes mellitus
EP1303304B1 (en) Pharmaceutical combinations for treatment and prevention of diabetes mellitus
RU98117673A (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF HYPERGLYCEMIA, MALIC ACID SALT 5- [4- [2- (N-METHYL-N- (2-Pyridyl) AMINO) ETOXY] BENZyl] THIAZOLI-IODIOLIENE-2-ILCENE-2-ILCENE-2-I-DIOLIDE-2-ILCENE-2-I-DOLIENE-2-ILCENE-2-ILCENE-2-I-2-Iolide-2-alkylene-2-imidene-2-dimene-2-amino-didene 2-amino-dione-in-2-d-imidene-2-amino-2-amino and 2-amino-2-inolin-2-amino inl and inlITin-2 in. TYPE II DIABETES TREATMENT FORM
SG149814A1 (en) Compositions and methods for treating diabetes
AR030920A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MELLITUS DIABETES AND CONDITIONS ASSOCIATED WITH MELLITUS DIABETES, AND PROCEDURES FOR PREPARING SUCH COMPOSITIONS
JP2003501361A5 (en)
AU2002244860A1 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV
TNSN00206A1 (en) Method for treating diabetes
BR0010914A (en) Compound medicine prophylactic or therapeutic agent, and, use of compound
ZA984798B (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome gestational diabetes and disease states at risk for progressing to noninsulindependent diabetes mellitus
EP1806347A4 (en) Aromatic-ring-fused pyrimidine derivative
NO2963A (en) Use of the compound 5- [4- [2- (5-ethylpyridin-2-yl) -ethoxy] benzyl] thiazolidine-2,4-dione (pioglitazone) for the manufacture of a medicament for the treatment of impaired glucose tolerance
CA2344144A1 (en) Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
CA2296653A1 (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
HUP0003260A2 (en) Pharmaceutical composition for treatment of diabetes with rosiglitazone and insulin
EP1634876A3 (en) Heterocyclic compounds for the treatment of hyperlipidemia agents
NZ513922A (en) Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione
RU2001118854A (en) OPTICALLY ACTIVE DERIVATIVE OF Pyridyl-4H-1,2,4-Oxadiazine AND ITS APPLICATION FOR TREATMENT OF VASCULAR DISEASES
JP2001039976A5 (en)
UY26112A1 (en) 5- [4- [2- (N-METHYL-N- (2-PIRIDIL) AMINO) ETOXI] BENCIL] THIAZOLIDINE-2,4-DIONA HYDROCHLORIDE
NZ501256A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
WO2001070236A8 (en) Preventing and/or treating diabetes mellitus
UY25048A1 (en) COMPOSITIONS FOR THE TREATMENT OF DIABETES MELLITUS